Deals this week: Genoa Pharmaceuticals, Dragonfly Therapeutics, Biomx
US-based pharmaceutical company Genoa Pharmaceuticals has completed a series A venture financing round led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners and participated by three other investors.
US-based pharmaceutical company Genoa Pharmaceuticals has completed a series A venture financing round led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners and participated by three other investors.
The company has raised a total of $62m from the round.
Celgene Corporation’s affiliate Celgene Switzerland, together with a number of family office investors, has provided venture financing to Dragonfly Therapeutics.
Based in the US, Dragonfly is a drug developer that intends to use the proceeds to expedite the development of its natural killer cell-based immunotherapies.
Israeli-based Biomx has completed a series A venture financing round to raise funds required to advance its novel therapeutic pipeline and further enhance its proprietary microbiome modulation platform technologies.
"Celgene Corporation’s affiliate Celgene Switzerland, together with a number of family office investors, has provided venture financing to Dragonfly Therapeutics."
The company develops therapies based on human bacteria and has raised $24m from the round.
Syros Pharmaceuticals has announced its intention to raise funds through issue of 2.5 million shares of its common stock to the public.
Syros is a life sciences company based in the US.
US-based biopharmaceutical company Synlogic has completed a series C preferred stock issue to multiple investors to raise $42m.
The proceeds are intended to be invested for the advancement of the company’s two lead metabolic disease programmes through patient proof-of-concept studies. Part of the funds will also be used to advance the development of earlier product candidates.